BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35715501)

  • 1. Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy.
    Walle T; Bajaj S; Kraske JA; Rösner T; Cussigh CS; Kälber KA; Müller LJ; Strobel SB; Burghaus J; Kallenberger SM; Stein-Thöringer CK; Jenzer M; Schubert A; Kahle S; Williams A; Hoyler B; Zielske L; Skatula R; Sawall S; Leber MF; Kunes RZ; Krisam J; Fremd C; Schneeweiss A; Krauss J; Apostolidis L; Berger AK; Haag GM; Zschäbitz S; Halama N; Springfeld C; Kirsten R; Hassel JC; Jäger D; ; Ungerechts G
    Nat Cancer; 2022 Sep; 3(9):1039-1051. PubMed ID: 35715501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.
    Au L; Fendler A; Shepherd STC; Rzeniewicz K; Cerrone M; Byrne F; Carlyle E; Edmonds K; Del Rosario L; Shon J; Haynes WA; Ward B; Shum B; Gordon W; Gerard CL; Xie W; Joharatnam-Hogan N; Young K; Pickering L; Furness AJS; Larkin J; Harvey R; Kassiotis G; Gandhi S; ; Swanton C; Fribbens C; Wilkinson KA; Wilkinson RJ; Lau DK; Banerjee S; Starling N; Chau I; ; Turajlic S
    Nat Med; 2021 Aug; 27(8):1362-1366. PubMed ID: 34040262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment.
    Strobel SB; Machiraju D; Kälber KA; Hassel JC
    Cancer Immunol Immunother; 2022 Aug; 71(8):2051-2056. PubMed ID: 34940894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 vaccination and cancer immunotherapy: should they stick together?
    Brest P; Mograbi B; Hofman P; Milano G
    Br J Cancer; 2022 Jan; 126(1):1-3. PubMed ID: 34799696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature.
    Tay SH; Toh MMX; Thian YL; Vellayappan BA; Fairhurst AM; Chan YH; Aminkeng F; Bharwani LD; Huang Y; Mak A; Wong ASC
    Front Immunol; 2022; 13():807050. PubMed ID: 35154124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of cytokine release syndrome accompanied with COVID-19 infection during treatment with immune checkpoint inhibitors for non-small cell lung cancer.
    Murata D; Azuma K; Tokisawa S; Tokito T; Hoshino T
    Thorac Cancer; 2022 Oct; 13(20):2911-2914. PubMed ID: 36073307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature.
    Liu LL; Skribek M; Harmenberg U; Gerling M
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36878533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report.
    Lasagna A; Lenti MV; Cassaniti I; Sacchi P
    Immunotherapy; 2022 Aug; 14(12):915-925. PubMed ID: 35694999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
    Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
    Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review.
    Ciner AT; Hochster HS; August DA; Carpizo DR; Spencer KR
    Immunotherapy; 2021 Sep; 13(13):1071-1078. PubMed ID: 34287029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study.
    Mei Q; Hu G; Yang Y; Liu B; Yin J; Li M; Huang Q; Tang X; Böhner A; Bryant A; Kurts C; Yuan X; Li J
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatal cytokine-release syndrome in a patient receiving toripalimab: a case report.
    Zhou Y; Zheng GH; Li N; Liu JJ; Wang XH; Li YF
    Immunotherapy; 2023 Jun; 15(9):641-645. PubMed ID: 37139989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review.
    Spagnolo F; Boutros A; Croce E; Cecchi F; Arecco L; Tanda E; Pronzato P; Lambertini M
    Eur J Clin Invest; 2021 Jul; 51(7):e13604. PubMed ID: 34021591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine release syndrome in a patient with non-small cell lung cancer on ipilimumab and nivolumab maintenance therapy after vaccination with the mRNA-1273 vaccine: a case report.
    Sumi T; Koshino Y; Michimata H; Nagayama D; Watanabe H; Yamada Y; Chiba H
    Transl Lung Cancer Res; 2022 Sep; 11(9):1973-1976. PubMed ID: 36248324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer.
    Funakoshi Y; Yakushijin K; Ohji G; Hojo W; Sakai H; Takai R; Nose T; Ohata S; Nagatani Y; Koyama T; Kitao A; Nishimura M; Imamura Y; Kiyota N; Harada K; Tanaka Y; Mori Y; Minami H
    J Infect Chemother; 2022 Apr; 28(4):516-520. PubMed ID: 35090826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab-Induced Cytokine Release Syndrome: A Case Report and Literature Review.
    Ntwali F; Gilliaux Q; Honoré PM
    Am J Case Rep; 2024 Apr; 25():e941835. PubMed ID: 38625840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer.
    Yomota M; Mirokuji K; Sakaguchi M; Kitahara Y; Chin F; Setoguchi K; Hosomi Y
    Intern Med; 2021 Nov; 60(21):3459-3462. PubMed ID: 33775995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade.
    Niewolik J; Mikuteit M; Cossmann A; Vahldiek K; Gutzmer R; Müller F; Schröder D; Heinemann S; Behrens GMN; Dopfer-Jablonka A; Steffens S; Grimmelmann I
    Oncology; 2022; 100(7):392-398. PubMed ID: 35609553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination and Immune Checkpoint Inhibitors: Does Vaccination Increase the Risk of Immune-related Adverse Events? A Systematic Review of Literature.
    Desage AL; Bouleftour W; Rivoirard R; Magne N; Collard O; Fournel P; Tissot C
    Am J Clin Oncol; 2021 Mar; 44(3):109-113. PubMed ID: 33350679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination.
    Sisteré-Oró M; Wortmann DDJ; Andrade N; Aguilar A; Mayo de Las Casas C; Casabal FG; Torres S; Bona Salinas E; Raventos Soler L; Arcas A; Esparre C; Garcia B; Valarezo J; Rosell R; Güerri-Fernandez R; Gonzalez-Cao M; Meyerhans A
    Front Immunol; 2022; 13():908108. PubMed ID: 35911701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.